STAT+: STAT+ Conversation: Which biotech venture capitalist funds performed best during the pandemic?

Editor’s note: A livestream of the conversation will be embedded below at 2 p.m. ET.

Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma, and health tech leaders. This week, STAT senior medicine writer and editorial director of events Matthew Herper and STAT general assignment reporter Kate Sheridan sit down to discuss the second edition of her report “Ranking biotech’s top venture capital firms.”  They will explore which venture capitalist funds performed best during the pandemic, and of course be taking your questions live.

Continue to STAT+ to read the full story…

STAT+: STAT+ Conversation: Which biotech venture capitalist funds performed best during the pandemic?

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top